论文部分内容阅读
目的观察非ST段抬高心肌梗死(NSTEMI)病人血浆组织型纤溶酶原激活物抑制物1(PAI-1)变化和丹参冻干粉剂对其影响。方法将110例病人随机分为治疗组和对照组,两组均给予西医常规治疗,治疗组加用丹参冻干粉剂。两组分别于治疗前、治疗后14d测定血浆PAI-1浓度,观察心绞痛、严重心律失常、心力衰竭的发生情况。结果治疗组和对照组治疗前PAI-1浓度接近,治疗后14d治疗组PAI-1水平低于对照组(t=2.434,P<0.05),心绞痛、严重心律失常、心力衰竭的发生率均显著低于对照组(χ2=3.891～4.385,P<0.05)。结论丹参冻干粉剂治疗NSTEMI的效果确切,并能降低心绞痛、严重心律失常、心力衰竭的发生率。
Objective To investigate the changes of plasma tissue plasminogen activator inhibitor 1 (PAI-1) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and the effect of Danshen freeze-dried powder. Methods One hundred and ten patients were randomly divided into treatment group and control group. Both groups were given Western medicine routine treatment. The treatment group was treated with Danshen freeze-dried powder. The plasma PAI-1 concentrations were measured before treatment and at 14th day after treatment in both groups. Angina pectoris, severe arrhythmia and heart failure were observed. Results The concentrations of PAI-1 in treatment group and control group before treatment were similar, and the levels of PAI-1 in treatment group 14 d after treatment were lower than those in control group (t = 2.434, P <0.05). The incidence of angina pectoris, severe arrhythmia and heart failure were significantly Lower than the control group (χ2 = 3.891 ~ 4.385, P <0.05). Conclusion Danshen freeze-dried powder for the treatment of NSTEMI exact effect, and can reduce angina, severe arrhythmia, heart failure incidence.